Neurogene, Inc. Common Stock (NGNE) is a publicly traded Healthcare sector company. As of May 20, 2026, NGNE trades at $26.95 with a market cap of $442.14M and a P/E ratio of -6.31. NGNE moved +0.28% today. Year to date, NGNE is +46.23%; over the trailing twelve months it is +45.28%. Its 52-week range spans $6.88 to $74.49. Analyst consensus is strong buy with an average price target of $81.67. Rallies surfaces NGNE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes NGNE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $26.95 |
| Market Cap | $442.14M |
| P/E Ratio | -6.31 |
| EPS | $-4.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $74.49 |
| 52-Week Low | $6.88 |
| Volume | 145.97K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-90.35M |
| Gross Margin | 0.00% |
8 analysts cover NGNE: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.67.